technetium tc-99m mertiatide

Action and Spectrum

Actions and Spectrum: 

Action: technetium tc-99m mertiatide, a radiopharmaceutical agent, exhibits a distinct action primarily attributed to its chelating properties and affinity for renal tubular cells. Upon intravenous administration, tc-99m mertiatide, a technetium-99m labeled mercaptoacetyltriglycine derivative, rapidly undergoes renal filtration and subsequent binding to megalin receptors located on the luminal surface of proximal tubular cells within the kidneys. 

Spectrum: 

Glomerular Filtration Rate (GFR) Measurement: technetium tc-99m mertiatide’s selective accumulation in proximal tubular cells allows for the estimation of GFR, a pivotal indicator of renal function. Its dynamic imaging captures the initial uptake phase and subsequent excretion, enabling GFR quantification through established algorithms. 

Renal Blood Flow Evaluation: technetium tc-99m mertiatide’s affinity for megalin receptors enables the assessment of renal blood flow and effective renal plasma flow, contributing to the characterization of renal vascular perfusion. 

Drug Interaction

Adverse Reaction

Frequency not defined  

Miscellaneous: Fever 

Respiratory: wheezing, Dyspnea, 

Gastrointestinal: vomiting, Nausea 

Dermatologic: skin rash, Pruritus 

Central nervous system: seizure, Chills 

Cardiovascular: tachycardia, Hypertension 

Black Box Warning

Black Box Warning:  

None

Contraindication / Caution

Contraindication/Caution:  

Allergic Reaction: Patients with a known hypersensitivity or allergy to technetium tc-99m mertiatide or any of its components should not receive this radiopharmaceutical. 

Pregnancy and Breastfeeding: The use of technetium tc-99m mertiatide in pregnant or breastfeeding women is generally avoided due to potential risks to the developing fetus or infant. If the benefits outweigh the risks, a healthcare provider will carefully consider the situation. 

Severe Renal Impairment: Patients with severely impaired renal function or end-stage renal disease may not be suitable candidates for technetium tc-99m mertiatide imaging, as the renal excretion and clearance of the radiopharmaceutical may be compromised. 

Uncontrolled Hypertension: Uncontrolled high blood pressure may affect the accuracy of the renal imaging results, and therefore, the use of technetium tc-99m mertiatide may be contraindicated in such cases. 

Acute Kidney Injury: Patients with acute kidney injury or other acute renal conditions may not be appropriate candidates for this imaging procedure, as it may not provide accurate results under these circumstances. 

Severe Dehydration: Dehydrated patients may experience altered renal function and blood flow, which could affect the accuracy of the imaging results obtained using technetium tc-99m mertiatide. 

Prior Exposure to Radiopharmaceuticals: Patients who have received other radiopharmaceuticals recently may need to delay or avoid technetium tc-99m mertiatide imaging due to potential interactions or cumulative radiation exposure. 

Pregnancy / Lactation

Pregnancy warnings:     

Pregnancy category: N/A 

Lactation: Excreted into human milk is known 

Pregnancy Categories:         

Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester. 

Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.   

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology:  

technetium tc-99m mertiatide, is a radiopharmaceutical agent used in nuclear medicine for imaging the kidneys. 

Pharmacodynamics:  

mertiatide is a chelating agent that forms a complex with technetium tc-99m. The compound is administered intravenously, and after injection, it is rapidly cleared from the bloodstream by the kidneys and excreted primarily through urine. The action involves the binding of tc-99m to the mertiatide molecule, forming a stable complex that is preferentially filtered by the glomeruli of the kidneys.   

Pharmacokinetics: 

Absorption 

technetium tc-99m mertiatide is administered intravenously as a radiopharmaceutical. Upon injection, it quickly enters the bloodstream and is distributed throughout the body. 

Distribution 

tc-99m mertiatide primarily accumulates in the kidneys due to its renal imaging purpose. It is filtered by the glomerulus and then actively secreted into the renal tubules. The radiopharmaceutical attaches to tubular cells, providing information about renal function and excretion. 

Metabolism 

tc-99m mertiatide is not significantly metabolized in the body. Its chemical structure remains relatively stable during the imaging process, allowing it to retain its radiopharmaceutical properties for the desired duration of imaging. 

Excretion and Elimination 

tc-99m mertiatide is eliminated from the body primarily through renal excretion. It is filtered by the glomerulus, actively secreted into the renal tubules, and ultimately excreted into the urine.

Adminstartion

Administration:  

The radiopharmaceutical is then administered to the patient via intravenous injection, usually into a vein in the arm.

Patient Information Leaflet

Patient information leaflet 

Generic Name: technetium tc-99m mertiatide 

Why do we use technetium tc-99m mertiatide?  

Renal Imaging: technetium Tc-99m mertiatide is primarily used for renal scintigraphy, a non-invasive imaging technique that provides information about the function and blood flow to the kidneys. This procedure is commonly employed to diagnose and monitor various kidney conditions, including obstruction, renal artery stenosis, and evaluation of kidney transplant function.